Regeneron Pharmaceuticals CEO Leonard Schleifer's 2019 pay slips 19% to $21M
Regeneron Pharmaceuticals reports 2019 executive compensation
By ExecPay News
Published: April 24, 2020
Regeneron Pharmaceuticals reported fiscal year 2019 executive compensation information on April 24, 2020.
In 2019, five executives at Regeneron Pharmaceuticals received on average a compensation package of $13M, a 16% decrease compared to previous year.
Average pay of disclosed executives at Regeneron Pharmaceuticals
Leonard S. Schleifer, Chief Executive Officer, received $21M in total, which decreased by 19% compared to 2018. 55% of Schleifer's compensation, or $12M, was in option awards. Schleifer also received $3.1M in non-equity incentive plan, $1.4M in salary, $5M in stock awards, as well as $338K in other compensation.
George D. Yancopoulos, Chief Scientific Officer, received a compensation package of $21M, which decreased by 19% compared to previous year. 57% of the compensation package, or $12M, was in option awards.
Andrew J. Murphy, Executive Vice President, Research, earned $9.5M in 2019.
Robert E. Landry, Chief Financial Officer, received $7.9M in 2019, which decreases by 15% compared to 2018.
Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply, earned $7.8M in 2019, a 13% decrease compared to previous year.
Related executives
Leonard Schleifer
Regeneron Pharmaceuticals
Chief Executive Officer
George Yancopoulos
Regeneron Pharmaceuticals
Chief Scientific Officer
Robert Landry
Regeneron Pharmaceuticals
Chief Financial Officer
Daniel Van Plew
Regeneron Pharmaceuticals
Executive Vice President and General Manager, Industrial Operations and Product Supply
Andrew Murphy
Regeneron Pharmaceuticals
Executive Vice President, Research
You may also like
Source: SEC filing on April 24, 2020.